Cargando…

548. Combined Results of the Phase 2a/2b/3 Randomized Controlled Trials of Ensitrelvir for the Treatment of COVID-19 Infection

BACKGROUND: Ensitrelvir is a selective SARS-CoV-2 3CL protease inhibitor developed as an oral therapy for the treatment of COVID-19 infection. We report the combined results for ensitrelvir 125 mg and 250 mg treatment from the Phase 2a, 2b, 3 parts of the Phase 2/3 study conducted in patients with C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsuge, Yuko, Yotsuyanagi, Hiroshi, Ohmagari, Norio, Doi, Yohei, Yamato, Masaya, Imamura, Takumi, Sonoyama, Takuhiro, Sanaki, Takao, Mukae, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678521/ http://dx.doi.org/10.1093/ofid/ofad500.617

Ejemplares similares

549. Ensitrelvir for the Treatment of COVID-19 Infection: Evaluation of Taste Disorder and Smell Disorder in the Phase 3 Part of the Phase 2/3 SCORPIO-SR Randomized Controlled Trial
por: Tsuge, Yuko, et al.
Publicado: (2023)

Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study
por: Mukae, Hiroshi, et al.
Publicado: (2022)

A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
por: Mukae, Hiroshi, et al.
Publicado: (2022)

A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)
por: Yotsuyanagi, Hiroshi, et al.
Publicado: (2023)

A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations
por: Shimizu, Ryosuke, et al.
Publicado: (2023)

Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults
por: Shimizu, Ryosuke, et al.
Publicado: (2022)

Evaluation of the Drug–Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults
por: Shimizu, Ryosuke, et al.
Publicado: (2023)

In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
por: Kiso, Maki, et al.
Publicado: (2023)

Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally
por: Kawashima, Sho, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model
por: Fukao, Keita, et al.
Publicado: (2023)

Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants
por: Lin, Mengmeng, et al.
Publicado: (2023)

Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo
por: Kuroda, Takayuki, et al.
Publicado: (2023)

1292. Safety Profile of the Novel Siderophore Cephalosporin Cefiderocol in Randomized Phase 2 and Phase 3 Clinical Studies of Serious Gram-Negative Infections
por: Matsunaga, Yuko, et al.
Publicado: (2020)

Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2
por: Yang, Yujian, et al.
Publicado: (2023)

The 2,548 best things anybody ever said /
Publicado: (2003)

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
por: Ip, Jonathan Daniel, et al.
Publicado: (2023)

A nickel and silicon rich phase in irradiated FV548 steel
por: Williams, T M, et al.
Publicado: (1979)

Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral Ensitrelvir
por: Kawajiri, Takahiro, et al.
Publicado: (2023)

Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease
por: Noske, Gabriela Dias, et al.
Publicado: (2023)

Successful dual antiviral therapy with remdesivir and ensitrelvir in a case of prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma
por: Jung, Seowoong, et al.
Publicado: (2023)

548 Toward a Burn Risk Calculator
por: Bessey, Palmer Q, et al.
Publicado: (2022)

FRI548 A Case Of Periureteric Myxedema
por: Ferris, Jaclyn M, et al.
Publicado: (2023)

Inverse Agonism of SQ 29,548 and Ramatroban on Thromboxane A2 Receptor
por: Chakraborty, Raja, et al.
Publicado: (2014)

Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings
por: Iwata, Satoshi, et al.
Publicado: (2022)

Abell 548: an x-ray and optical analysis of substructure
por: Davis, D S, et al.
Publicado: (1994)

548 Immunoglobulin a Deficiency, HPV and Oral Cancer
por: Alvarez, Jorge, et al.
Publicado: (2012)

miR-1279, miR-548j, miR-548m, and miR-548d-5p Binding Sites in CDSs of Paralogous and Orthologous PTPN12, MSH6, and ZEB1 Genes
por: Ivashchenko, Anatoliy T., et al.
Publicado: (2013)

SARS-CoV-2 3CL(pro) mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
por: Heilmann, Emmanuel, et al.
Publicado: (2022)

Descriptive Review and Analysis of Immunoglobulin Utilization Management from 2,548 Prior Authorization Requests
por: Tonkovic, Brian, et al.
Publicado: (2014)

Hsa-mir-548 family expression in human reproductive tissues
por: Rooda, Ilmatar, et al.
Publicado: (2021)

537. Safety and Effectiveness of Ensitrelvir for the Treatment of COVID-19 in Japanese Clinical Practice: A Post-marketing Surveillance (Interim Analysis)
por: Ogura, Eriko, et al.
Publicado: (2023)

Sequence-based mutation patterns at 41 Y chromosomal STRs in 2 548 father–son pairs
por: Liu, Ze, et al.
Publicado: (2023)

SUN-548 A Case Report on Neonatal Hyperthyroidism Amidst Confusions
por: Sukumaran, Anju, et al.
Publicado: (2019)

548. Convalescent Plasma in Hospitalized Pediatric and Obstetric patients with COVID-19
por: Ikeda, Saki, et al.
Publicado: (2021)

Small change for big improvement in the preparation of the key intermediate N(1), N(3)-disubstituted 1,3,5-triazone of ensitrelvir
por: Hu, Wei, et al.
Publicado: (2023)

Comparative Genome Analysis of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Sequence Type 131 Strains from Nepal and Japan
por: Miyoshi-Akiyama, Tohru, et al.
Publicado: (2016)

Correction for Miyoshi-Akiyama et al., “Comparative Genome Analysis of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Sequence Type 131 Strains from Nepal and Japan”
por: Miyoshi-Akiyama, Tohru, et al.
Publicado: (2017)

Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study
por: Shinkai, Masaharu, et al.
Publicado: (2022)

MiR‐548 K regulatory effect on the ABCG2 gene expression in MDR breast cancer cells
por: Saberiyan, Mohammadreza, et al.
Publicado: (2023)

Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir “S-217622”: A Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species
por: Eltayb, Wafa A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6315i24mjnlfr9f3ahvs72odqi